Based in Japan and India. Has led to 1 successful fundraise in Japan. Been working the space of Venture Capital and Private Equity for the last 3 years.

The animal health and nutrition sector is evolving and the tools for improving animal health and nutrition are growing faster with Ascus Biosciences.

Ascus uses its proprietary technology platform to address the complexities of native microbial communities living in highly productive and healthy animals. From these curated insights, effective native microorganisms are selected and isolated from animal samples and developed into products. These novel, multi-strain and naturally occurring whole microbe products are shelf-stabilized and compatible with standard in-feed delivery systems. This method is the first of its kind in the animal health and nutrition sector, where most microbial products on the market are not developed on the basis of a comprehensive understanding of animal microbiomes.

The financing was led by global investment firm Temasek, with the participation of other leading investors, Anterra Capital, Formation 8 and Cavallo Ventures (Wilbur-Ellis venture capital arm), as well as additional support from various angel investors.

“Animals are an increasingly large part of our economy and food supply, yet most of the existing feed additives are at least 50 years old,” says Formation 8 founder and general partner Jim Kim. “Using modern science as a way to better understand animal health and nutrition is better for the world’s food supply and works in harmony with animal welfare. “That’s right.

With $46 million secured in its Series B fund-raising, Ascus is well positioned to continue expanding its customer sales and service teams, to advance new and existing products in its product pipeline, and to continue refining its core technology platform and intellectual property foundation.

“Securing this level of funding will help bring Ascus technology to farmers and pet owners looking for newer, safer and more effective microbial solutions on a much larger scale as we continue to expand our sales and customer service footprint in the US and around the world,” says Michael Seely, Chief Executive Officer of Ascus Biosciences. “With this funding round, we are now well-equipped to expand and serve our existing and prospective customers while continuing to advance the breakthrough products currently in our research and development pipeline. “That’s right.

Ascus has multiple microbial solutions in development, some of which are already in sales mode from dairy, poultry, beef feedlots, horses, to companion species.

Ascus Biosciences

Headquartered in San Diego, Ascus maintains a number of field, sales and production operations around the globe. Visit AscusBiosciences to see Come and learn more about the technology and science behind these innovative products.

Please note that this piece of work originally appeared in English at As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at

Leave a Reply

Your email address will not be published. Required fields are marked *